Telix Pharmaceuticals revenue and financials

TLX · ASX · AUD

$13.39Change from previous close: −1.40%Absolute change: −$0.19

Close · November 16, 2026

In the fiscal year ended December 2025, Telix Pharmaceuticals reported revenue of $803.79M (+55.61% year over year). The net loss was $7.13M.

Annual revenue · 2025: $803.79M
  1. $137.46K2018
  2. $2.45M2019
  3. $4.01M2020
  4. $5.51M2021
  5. $109.07M2022
  6. $332.98M2023
  7. $516.55M2024
  8. $803.79M2025

Fiscal year ending in December. Sources and method on the page How we analyse stocks.

At a glance

Revenue growth
+55.61%
2025 vs 2024
Net margin
-0.9%
2024: 6.5%

How Telix Pharmaceuticals is changing

Calculated from the annual statements; each fiscal year is labelled with the year it ends.

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item2025202420232022202120202019201820172016
Total revenue8045173331095.54.02.40.1——
Cost of revenue42219713044.41.81.61.8———
Gross profit38231920364.73.72.50.70.1——
Selling, general and administrative19313683.159.334.118.811.16.42.80.0
Research and development17112885.355.224.817.814.913.22.30.0
Operating income19.355.935.0-50.5-59.0-37.9-28.3-19.5-5.1-0.0
EBIT19.355.935.0-50.5-59.0-37.9-28.3-19.5-5.1-0.0
EBITDA32.559.638.2-47.4-55.7-34.6-25.5-19.5-5.1—
Interest expense13.84.80.50.20.10.10.10.00.00.0
Pre-tax income-5.337.92.6-67.2-58.4-36.9-21.9-11.1-5.0-0.0
Income tax1.94.2-1.63.70.0-2.3-2.3-1.3——
Net income-7.133.74.2-70.9-58.5-34.5-19.6-9.7-5.0-0.0
Net income to common shareholders-7.133.74.2-70.9-58.5-34.5-19.6-9.7-5.0-0.0
Basic EPS-0.020.100.01-0.23-0.21-0.13-0.08-0.05-0.04—
Diluted EPS-0.020.100.01-0.23-0.21-0.13-0.08-0.05-0.04—
Average shares (basic)338331319311282257233202128—
Average shares (diluted)338345324311282257233202128—

Companies in the group: same industry, similar size